|
|
|
13.01.26 - 21:24
|
Senate publishes draft market structure bill with limits on stablecoin rewards: CNBC Crypto World (CNBC)
|
|
|
On today's episode of CNBC Crypto World, major cryptocurrencies trade higher after new data showed inflation was lower than expected in December. Plus, the Senate Banking Committee releases the full text of proposed market structure legislation ahead of its markup this week. And, Polygon Labs CEO Marc Boiron discusses the firm's acquisitions of crypto payments company Coinme and digital asset infrastructure provider Sequence in moves geared at expanding Polygon's footing in stablecoin payments....
|
|
|
|
|
13.01.26 - 18:24
|
U.S. FDA grants Ipsen′s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia (GlobeNewswire EN)
|
|
|
PARIS, FRANCE, 13 JANUARY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for IPN60340 in combination with venetoclax and azacitidine (Ven-Aza) in first line unfit acute myeloid leukemia, an aggressive blood cancer affecting older adults. IPN60340 is an investigational first-in-class monoclonal antibody targeting BTN3A, a key immune-regulatory molecule broadly expressed across cancer. Breakthrough Therapy Designation is intended to expedite the development and review of medicines for serious or life-threatening conditions with evidence of a substantial clinical improvement. IPN60340 previously received Orphan Drug Designations from the U.S. Food and Drug Administration and European Medicines Agency in July 2025....
|
|
|
|
|
13.01.26 - 18:03
|
IMPLANET Reports Full-Year 2025 Revenue of €12.5 Million, Up Sharply by +33% (Business Wire)
|
|
|
U.S. sales +49% in 2025 (+56% at constant exchange rates)
First deliveries of JAZZ® to China following CFDA approval, totaling €0.5 million
BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced medical equipment, today announces its full-year 2025 revenue as well as its cash position as of December 31, 2025.
Ludovic Lastennet, CEO of IMPLANET, stated: “We delivered a very strong commercial performance in 2025, with revenue of €12.5 million, representing +33% growth compared with the same period last year, thereby confirming the relevance of the development model we have been implementing for the past two years. Building on six consecutive quarters of sustained growth, we are firmly confident in the outlook for the coming quarters. The strong momentum in implant sales, up +36% in the fourth quarter, has been driven...
|
|
|
|
|
13.01.26 - 15:03
|
Zip Launches Enterprise Transformation Office, Tapping Former Fortune 500 CPOs to Guide Procurement Leaders Through AI-Era Change (Business Wire)
|
|
|
Former procurement leaders from UnitedHealth Group, MGM Resorts International, and Sanofi join Zip to help enterprises navigate the shift to agentic procurementSAN FRANCISCO--(BUSINESS WIRE)--Zip, the leading AI platform for enterprise procurement, today announced the launch of its Enterprise Transformation Office (ETO), a dedicated team of former Fortune 500 procurement leaders who will work directly with customers to drive large-scale procurement transformation.
The ETO is led by Jason Moore, Head of the Enterprise Transformation Office at Zip, who previously served as Senior Director of Enterprise Procurement at Discover. Moore has assembled a team of seasoned executives who collectively bring decades of experience running procurement at some of the world's largest organizations:
Peder Gustafson, former Chief Procurement Officer at UnitedHealth Group (Fortune 3), with additional CPO experience at Ameriprise Financial and VP-level procurement roles at Medtronic.
James Czarnecki, former SVP and Chief Pr...
|
|
|
|
|
13.01.26 - 09:54
|
Sartorius Stedim Biotech Outperform (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für Sartorius Stedim auf "Outperform" mit einem Kursziel von 245 Euro belassen. 2025 sei ein schlechtes Jahr für die meisten europäischen Medizintechnikwerte gewesen, ......
|
|
|
13.01.26 - 06:45
|
Abivax: Kurs fährt Achterbahn – Frankreich dementiert Übernahme-Gespräche (Sharedeals)
|
|
|
Nach einem Plus von zeitweise über 30% hat die Aktie des französischen Biotechunternehmens Abivax ihre Tagesgewinne gestern fast komplett wieder abgegeben. Zuvor hatten neue Übernahmespekulationen für deutliche Kursaufschläge gesorgt, nachdem die französische Zeitung La Lettre wiederholt den US-Pharmakonzerns Eli Lilly als Übernahmeinteressenten ins Spiel gebracht hatte. Mit 15 Milliarden Euro wurde erstmals sogar ein potenzieller, […]
The post Abivax: Kurs fährt Achterbahn – Frankreich dementiert Übernahme-Gespräche first appeared on sharedeals.de....
|
|
|
12.01.26 - 18:03
|
Medincell: Publication of the 2026 Financial Calendar (Business Wire)
|
|
|
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Medincell (Paris:MEDCL):
Event
Date
Annual results 2025-2026
(April 2025-March 2026)
Tuesday, June 16, 2026
General Meeting
Thursday, September 10, 2026
Half-Year results 2026-2027
(April-September 2026)
Tuesday, December 8, 2026
About Medincell
Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact.
These treatments combine active pharmaceutical ingredients with our proprietary BEPO® / BEPO® Star technologies, which enables controlled drug delivery at therapeutic levels for several days, weeks, or months following a subcutaneous or local injection of a small, fully bioresorbable deposit.
Risperidone LAI was the first treatment based on BEPO® technology to receive F...
|
|
|
12.01.26 - 17:48
|
Eurofins: Weekly Report on Share Repurchases From 05th January to 09th January 2026 (Business Wire)
|
|
|
LUXEMBOURG--(BUSINESS WIRE)--Regulatory News:
Eurofins (Paris:ERF):
Name of the Issuer
Identify code of the Issuer
Transaction day
Identify code of the financial instrument
Total daily volume (in number of shares)
Daily weighted average purchase price of the shares
Market (MIC Code)
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
05/01/2026
FR0014000MR3
74
65.0200
CEUX
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
05/01/2026
FR0014000MR3
29 926
65.9433
XPAR
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
06/01/2026
FR0014000MR3
10 000
68.1028
XPAR
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
07/01/2026
FR0014000MR3
10 000
68.8178
XPAR
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
08/01/2026
FR0014000MR3
10 000
68.8567
XPAR
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
09/01/2026
FR0014000MR3
10 000
69.5790
XPAR
TOTAL
70 000
67.5971
Transaction details
In accordance with Article 5(1)(b) of Regulation (EU) N° 596/2014 (the Market Abuse Regulation) a full breakdown of the individual trades are disclosed on Eurofins Scientific SE w...
|
|
|
12.01.26 - 17:42
|
FR Regulatory News: VALBIOTIS SA (EQS)
|
|
|
VALBIOTIS SA: Valbiotis announces a major new scientific publication on TOTUM-448, an active substance designed to treat metabolic liver disease (MASLD)...
|
|
|
12.01.26 - 16:00
|
Eurofins Scientific: Director/PDMR Shareholding (Business Wire)
|
|
|
LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1.
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Analytical Bioventures S.C.A (RCS B89265)
23, Va Fleuri, L-1526 Luxembourg
2.
Reason for the notification
a)
Position / status
Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin
b)
Initial notification / amendment
Initial
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Eurofins Scientific S.E.
b)
LEI
529...
|
|
|
|
|
|
|
|
|
|
|
|
|
12.01.26 - 11:57
|
Sartorius Stedim Biotech Neutral (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat die Aktien von Sartorius Stedim nach ihrem guten Lauf bei einem unveränderten Kursziel von 246 Euro von "Buy" auf "Neutral" abgestuft. Analyst James Quigley sieht im europäischen Life-Science-Bereich ......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
